Salute e Benessere
SpyBiotech Appoints Keith Dewedoff as new Chief Financial Officer
"I am proud to join the SpyBiotech team as the company continues to expand," said Keith Dewedoff . "Given the recently announced research collaboration with the University of Oxford and SpyBiotech's Phase I trial of its HCMV vaccine, this is a really exciting time to join the company."
"Keith is an excellent addition to our leadership team. His depth of expertise in financial strategy and corporate development will serve SpyBiotech well as we continue to build our organization and progress our scientific pipeline," said Mark Leuchtenberger , Chief Executive Officer. "We look forward to this new chapter of advancement with our lead candidate in the clinic and our EBV-focused collaboration with the University of Oxford ."
SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science Enterprises (OSE) and Google Ventures (GV). The company raised $32.5 million in a Series A equity financing in 2021. Based on science developed at the University of Oxford , SpyBiotech's novel vaccine platform is based on a proprietary protein "superglue" technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related "superglue" technologies in vaccine development.
View original content:https://www.prnewswire.co.uk/news-releases/spybiotech-appoints-keith-dewedoff-as-new-chief-financial-officer-302174548.html